Business · India Bureau
Nifty Pharma gains ground as specialty drugs win US tariff exemption
Indian pharmaceutical stocks advanced on relief that select specialty medicines will face zero duty in the United States market. The exemption provides a cushion for domestic drugmakers facing broader tariff pressures.
LSN India ·
Nifty Pharma index rose 1 per cent as markets broadly retreated, buoyed by news that qualifying specialty pharmaceutical products manufactured in India will gain duty-free access to the US market. The development offers meaningful relief to Indian pharmaceutical exporters who have significant exposure to American buyers, a crucial market for the sector.
The tariff exemption focuses on select specialty medicines, narrowing the scope of duties that could have impacted a wider range of pharmaceutical exports. Indian drugmakers, already operating on thin margins in highly competitive global markets, stand to benefit from retained competitiveness on these designated products.
The pharmaceutical sector has faced uncertainty amid broader trade tensions and tariff announcements affecting multiple industries. The carve-out for specialty drugs signals that policymakers have recognised the significance of India's pharmaceutical industry to global supply chains and patient access to essential medicines.
Analysts noted the exemption could stabilise sentiment within the sector, though the full impact will depend on the breadth of products ultimately covered. Indian pharmaceutical companies supply everything from generic drugs to complex biologics globally, with the US market representing a substantial portion of revenues for many listed firms.